Wall Street analyst estimates for Dyadic International, Inc. (DYAI): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Dyadic International, Inc. operates as a U.S.-based biotechnology platform company, specializing in the development, production, and commercialization of enzymes and other proteins. Its core activities are underpinned by a patented and proprietary C1 platform, alongside other advanced technologies.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.03 | ||
| 2026-08-12 | $-0.06 | $-0.04 | -71.4% |
| 2026-05-13 | $-0.05 | $-0.04 | -25.0% |
| 2026-03-25 | $-0.06 | $-0.03 | -100.0% |
| 2025-11-12 | $-0.06 | $-0.04 | -50.0% |
| 2025-08-13 | $-0.06 | $-0.06 | +0.0% |
| 2025-05-14 | $-0.07 | ||
| 2025-03-26 | $-0.05 | $-0.04 | -25.0% |
Valuation Ratios
| Price / Book | -6.38 |
| EV / EBITDA | -3.14 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $592886 | $758420 | $1.3M | $1.7M | $1.6M | $2.4M | $2.9M | $2.9M | $3.5M | $1.2M |
| Cost of Revenue | $516162 | $680197 | $1.0M | $1.5M | $1.4M | $1.9M | $2.1M | $2.0M | $1.2M | $2.3M |
| Gross Profit | $76724 | $78223 | $268173 | $221375 | $176990 | $459393 | $807110 | $922957 | $2.3M | -$1.1M |
| Research & Development | $885602 | $2.2M | $3.3M | $5.4M | $3.9M | $8.4M | $4.5M | $3.3M | $2.0M | $2.2M |
| Selling, General & Admin | $4.6M | $5.0M | $4.5M | $5.5M | $6.1M | $6.7M | $6.4M | $5.8M | $6.1M | $5.8M |
| Operating Expenses | $5.9M | $7.5M | $7.8M | $9.5M | $10.2M | $15.2M | $11.0M | $9.2M | $8.2M | $6.1M |
| Operating Income | -$6.0M | -$7.1M | -$7.6M | -$9.3M | -$10.0M | -$14.7M | -$10.2M | -$8.2M | -$5.9M | -$7.1M |
| EBITDA | 0 | -$2.2M | -$7.6M | 0 | -$10.0M | -$11.1M | -$10.1M | -$8.2M | -$5.4M | -$6.9M |
| Interest Expense | $909 | $566146 | $894532 | 0 | 0 | 0 | 0 | 0 | $427971 | $455897 |
| Pre-tax Income | -$3.4M | -$2.2M | -$6.7M | -$8.3M | -$9.3M | -$13.1M | -$9.7M | -$6.8M | -$5.8M | -$7.4M |
| Income Tax | $238073 | -$66694 | -$1.0M | $10306 | $31318 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$3.6M | -$2.1M | -$5.7M | -$8.3M | -$9.3M | -$13.1M | -$9.7M | -$6.8M | -$5.8M | -$7.4M |
| EPS | $-0.10 | $-0.07 | $-0.21 | $-0.31 | $-0.34 | $-0.47 | $-0.34 | $-0.24 | $-0.20 | $-0.23 |
| EPS (Diluted) | $-0.10 | $-0.07 | $-0.21 | $-0.31 | $-0.34 | $-0.47 | $-0.34 | $-0.24 | $-0.20 | $-0.23 |
| Shares Outstanding (Diluted) | $36.5M | $28.9M | $27.7M | $27.0M | $27.5M | $27.8M | $28.4M | $28.8M | $29.3M | $32.6M |
Price
| Price | $0.40 |
| Market Cap | $15M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ANVS · ATHE · BCAB · CELU · ELUT · MAIA · PYPD
Explore sector: Healthcare · Biotechnology
More sections of DYAI: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks